Alembic Pharmaceuticals has received approvals from US Food & Drug Administration (USFDA) for its Abbreviated New Drug Applications (ANDAs). The USFDA has given final approvals for Deferasirox Tablets 90 mg & 360 mg, Deferasirox Tablets for Oral Suspension, 125 mg, 250 mg, & 500 mg, and tentative approval for Deferasirox Tablets 180 mg.
Alembic now has a total of 107 ANDA approvals (95 final approvals and 12 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
